Published in Z Rheumatol on October 01, 2006
Mycophenolate sodium treatment in patients with primary Sjögren syndrome: a pilot trial. Arthritis Res Ther (2007) 0.90
[Interdisciplinary point of contact between rheumatology and pneumology]. Z Rheumatol (2008) 0.79
The clinical significance of anti-cyclic citrullinated peptide antibody in primary Sjögren syndrome. Rheumatol Int (2011) 0.75
Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis (2002) 20.48
SJOEGREN'S SYNDROME. A CLINICAL, PATHOLOGICAL, AND SEROLOGICAL STUDY OF SIXTY-TWO CASES. Medicine (Baltimore) (1965) 7.46
Labial salivary gland biopsy in Sjögren's disease. J Clin Pathol (1968) 6.61
Increased risk of lymphoma in sicca syndrome. Ann Intern Med (1978) 4.63
Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome. J Clin Invest (2002) 4.14
THE DEVELOPMENT OF MALIGNANT LYMPHOMA IN THE COURSE OF SJOEGREN'S SYNDROME. Am J Med (1964) 4.07
The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med (2005) 3.26
The pathology of dry eye: the interaction between the ocular surface and lacrimal glands. Cornea (1998) 2.86
Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study. Arthritis Rheum (2005) 2.55
Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS). Arthritis Rheum (2004) 2.44
Desiccating stress induces T cell-mediated Sjögren's Syndrome-like lacrimal keratoconjunctivitis. J Immunol (2006) 2.33
Pilot clinical trial of dehydroepiandrosterone (DHEA) versus placebo for Sjögren's syndrome. Arthritis Rheum (2004) 2.15
Lymphoma and other malignancies in primary Sjögren's syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis (2005) 2.14
Functional aspects of the tear film lipid layer. Exp Eye Res (2004) 2.06
Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis (2004) 2.06
Mortality and causes of death in primary Sjögren's syndrome: a prospective cohort study. Arthritis Rheum (2004) 2.03
Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with Sjögren's syndrome. Arthritis Rheum (2003) 2.03
Antigen-driven clonal proliferation of B cells within the target tissue of an autoimmune disease. The salivary glands of patients with Sjögren's syndrome. J Clin Invest (1998) 1.92
Retracted Infliximab in patients with primary Sjögren's syndrome: a pilot study. Arthritis Rheum (2001) 1.77
Clinical evolution, and morbidity and mortality of primary Sjögren's syndrome. Semin Arthritis Rheum (2000) 1.74
Sex hormones influence on the immune system: basic and clinical aspects in autoimmunity. Lupus (2004) 1.73
B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjögren's syndrome. Arthritis Res Ther (2006) 1.72
Comparison of autologous serum eye drops with conventional therapy in a randomised controlled crossover trial for ocular surface disease. Br J Ophthalmol (2004) 1.70
Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren's syndrome. Arthritis Rheum (2002) 1.59
Diminished peripheral blood memory B cells and accumulation of memory B cells in the salivary glands of patients with Sjögren's syndrome. Arthritis Rheum (2002) 1.47
Immunopathogenesis of primary Sjögren's syndrome: implications for disease management and therapy. Curr Opin Rheumatol (2005) 1.46
Sex hormones and the genesis of autoimmunity. Arch Dermatol (2006) 1.45
The Th1/Th2 cytokine balance changes with the progress of the immunopathological lesion of Sjogren's syndrome. Clin Exp Immunol (2002) 1.39
Etanercept in Sjögren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum (2004) 1.36
Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study. Arthritis Res Ther (2006) 1.30
Genetic aspects of Sjögren's syndrome. Arthritis Res (2002) 1.30
Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjögren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group. Arch Intern Med (1999) 1.23
Lymphoproliferative disorders in Sjögren's syndrome. Autoimmun Rev (2004) 1.23
Predictors of lymphoma development in primary Sjögren's syndrome. Semin Arthritis Rheum (1998) 1.22
A longitudinal cohort study of Finnish patients with primary Sjögren's syndrome: clinical, immunological, and epidemiological aspects. Ann Rheum Dis (2001) 1.22
Incidence of cancer in a cohort of patients with primary Sjogren's syndrome. Rheumatology (Oxford) (2006) 1.22
Elevated incidence of hematologic malignancies in patients with Sjögren's syndrome compared with patients with rheumatoid arthritis (Finland). Cancer Causes Control (1997) 1.18
Antimuscarinic antibodies in primary Sjögren's syndrome reversibly inhibit the mechanism of fluid secretion by human submandibular salivary acinar cells. Arthritis Rheum (2006) 1.17
Estrogen receptor-beta is the predominant estrogen receptor subtype in human oral epithelium and salivary glands. J Endocrinol (2004) 1.16
Inhibitory effects of muscarinic receptor autoantibodies on parasympathetic neurotransmission in Sjögren's syndrome. Arthritis Rheum (2000) 1.16
Lower frequency of focal lip sialadenitis (focus score) in smoking patients. Can tobacco diminish the salivary gland involvement as judged by histological examination and anti-SSA/Ro and anti-SSB/La antibodies in Sjögren's syndrome? Ann Rheum Dis (2000) 1.16
Androgen influence on the meibomian gland. Invest Ophthalmol Vis Sci (2000) 1.15
Malignancy and autoimmunity. Curr Opin Rheumatol (2006) 1.11
Primary Sjögren's syndrome in the North East of England: a long-term follow-up study. Rheumatology (Oxford) (1999) 1.08
Regulation of mucin and fluid secretion by conjunctival epithelial cells. Prog Retin Eye Res (2002) 1.08
Abnormalities in peripheral B cell memory of patients with primary Sjögren's syndrome. Arthritis Rheum (2004) 1.08
Cevimeline for the treatment of xerostomia in patients with Sjögren syndrome: a randomized trial. Arch Intern Med (2002) 1.06
Measurement of fatigue and discomfort in primary Sjogren's syndrome using a new questionnaire tool. Rheumatology (Oxford) (2004) 1.05
Treatment of primary Sjögren's syndrome with low-dose human interferon alfa administered by the oromucosal route: combined phase III results. Arthritis Rheum (2003) 1.05
Primary Sjögren syndrome in the paediatric age: a multicentre survey. Eur J Pediatr (2003) 1.04
Fatigue. BMJ (2002) 1.03
Primary Sjögren's syndrome: current and emergent aetiopathogenic concepts. Rheumatology (Oxford) (2005) 1.03
Hydroxychloroquine treatment for primary Sjögren's syndrome: a two year double blind crossover trial. Ann Rheum Dis (1993) 1.01
Prednisone and piroxicam for treatment of primary Sjögren's syndrome. Clin Exp Rheumatol (1993) 1.01
The BAFF/APRIL system in systemic autoimmune diseases with a special emphasis on Sjögren's syndrome. Scand J Immunol (2005) 0.99
Sleep disturbances in patients with primary Sjögren's syndrome. Br J Rheumatol (1993) 0.98
Treatment of primary Sjögren's syndrome with hydroxychloroquine: a retrospective, open-label study. Lupus (1996) 0.98
Prevalence of primary Sjögren's syndrome in an elderly population. Br J Rheumatol (1988) 0.98
Methotrexate in primary Sjögren's syndrome. Clin Exp Rheumatol (1997) 0.98
A double blind placebo controlled trial of azathioprine in the treatment of primary Sjögren's syndrome. J Rheumatol (1998) 0.96
Muscarinic acetylcholine type-3 receptor desensitization due to chronic exposure to Sjögren's syndrome-associated autoantibodies. J Rheumatol (2006) 0.96
Cyclosporin A (CyA) in primary Sjögren's syndrome: a double blind study. Ann Rheum Dis (1986) 0.95
Quality of life and psychological status in patients with primary Sjögren's syndrome and sicca symptoms without autoimmune features. Arthritis Rheum (2006) 0.94
Etanercept in the treatment of patients with primary Sjögren's syndrome: a pilot study. J Rheumatol (2004) 0.92
Outcome measures in Sjögren's syndrome. Rheumatology (Oxford) (2001) 0.91
Retracted Infliximab in primary Sjögren's syndrome: one-year followup. Arthritis Rheum (2002) 0.91
Oral pilocarpine for the treatment of ocular symptoms in patients with Sjögren's syndrome: a randomised 12 week controlled study. Ann Rheum Dis (2003) 0.91
Atypical autoantibodies in patients with primary Sjögren syndrome: clinical characteristics and follow-up of 82 cases. Semin Arthritis Rheum (2006) 0.91
Hydroxychloroquine treatment for primary Sjögren's syndrome: its effect on salivary and serum inflammatory markers. Ann Rheum Dis (1999) 0.90
The Boston Scleral Lens in the management of severe ocular surface disease. Ophthalmol Clin North Am (2003) 0.89
Significance of humidity and temperature on skin and upper airway symptoms. Indoor Air (2003) 0.89
Long term remission of Sjögren's syndrome associated aggressive B cell non-Hodgkin's lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). Ann Rheum Dis (2005) 0.88
Prevalence of Sjögren's syndrome in ambulatory patients according to the American-European Consensus Group criteria. Rheumatology (Oxford) (2004) 0.87
Abnormalities of B cell phenotype, immunoglobulin gene expression and the emergence of autoimmunity in Sjögren's syndrome. Arthritis Res (2002) 0.87
Th2 cytokine genotypes are associated with a milder form of primary Sjogren's syndrome. Ann Rheum Dis (2005) 0.86
Revisiting Sjögren's syndrome in the new millennium: perspectives on assessment and outcome measures. Report of a workshop held on 23 March 2000 at Oxford, UK. Rheumatology (Oxford) (2001) 0.86
Clinical features of Sjögren's syndrome. Curr Opin Rheumatol (1990) 0.85
Psychological well-being in patients with primary Sjögren's syndrome. Clin Exp Rheumatol (2001) 0.85
Dissemination of a Sjögren's syndrome-associated extranodal marginal-zone B cell lymphoma: circulating lymphoma cells and invariant mutation pattern of nodal Ig heavy- and light-chain variable-region gene rearrangements. Arthritis Rheum (2006) 0.84
Therapeutic effect of cevimeline on dry eye in patients with Sjögren's syndrome: a randomized, double-blind clinical study. Am J Ophthalmol (2004) 0.84
B cell targeted therapies in autoimmune diseases. J Rheumatol Suppl (2006) 0.84
Fatigue in daily life in patients with primary Sjögren's syndrome and systemic lupus erythematosus. Ann N Y Acad Sci (2002) 0.83
Proposed core set of outcome measures in patients with primary Sjögren's syndrome: 5 year follow up. J Rheumatol (2005) 0.81
Cyclosporin a therapy in patients with primary Sjögren's syndrome: results at one year. Scand J Rheumatol Suppl (1986) 0.80
Sex steroid hormones in primary Sjögren's syndrome. J Rheumatol (2003) 0.80
Differential risk of non-Hodgkin's lymphoma in Italian patients with primary Sjögren's syndrome. J Rheumatol (1997) 0.80
Effect of cyclosporin A (CyA) on the immunopathological lesion of the labial minor salivary glands from patients with Sjögren's syndrome. Ann Rheum Dis (1987) 0.79
A pilot trial for severe, refractory systemic autoimmune disease with stem cell transplantation. Chin Med Sci J (2005) 0.79
Cutaneous T cell lymphoma in a patient with primary biliary cirrhosis and secondary Sjögren's syndrome. J Rheumatol (2002) 0.78
Xerostomia secondary to Sjögren's syndrome in the elderly: recognition and management. Drugs Aging (2005) 0.77
Conjunctival epithelium improvement after systemic pilocarpine in patients with Sjogren's syndrome. Br J Ophthalmol (2006) 0.77
Oestrogen receptors in cultured epithelial cells from salivary glands of Sjogren's syndrome patients. Rheumatology (Oxford) (2003) 0.77
Sjogren's syndrome and the danger model. Rheumatology (Oxford) (2005) 0.75
Alternate-day steroid therapy for patients with primary Sjögren's syndrome. Ann Ophthalmol (1983) 0.75
Lacrimal and salivary secretion in Sjögren's syndrome: the effect of systemic treatment with bromhexine. Acta Ophthalmol (Copenh) (1984) 0.75
Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol (2000) 3.05
Analysis of the human VH gene repertoire. Differential effects of selection and somatic hypermutation on human peripheral CD5(+)/IgM+ and CD5(-)/IgM+ B cells. J Clin Invest (1997) 2.44
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. Ann Rheum Dis (2012) 1.67
No B cells--no active RA? Advances in B cell depletion in RA--repeated therapy under conditions of clinical practice. Rheumatology (Oxford) (2007) 1.39
Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls. Ann Rheum Dis (2007) 1.36
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann Rheum Dis (2010) 1.34
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis (2008) 1.31
HLA-DRhigh/CD27high plasmablasts indicate active disease in patients with systemic lupus erythematosus. Ann Rheum Dis (2010) 1.30
Pairing of variable heavy and variable kappa chains in individual naive and memory B cells. J Immunol (1998) 1.20
Optimising treatment in rheumatoid arthritis: a review of potential biological markers of response. Ann Rheum Dis (2011) 1.19
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010. Ann Rheum Dis (2011) 1.17
The human immunomodulatory CD25+ B cell population belongs to the memory B cell pool. Scand J Immunol (2007) 1.16
Increased serum soluble CD14, ICAM-1 and E-selectin correlate with disease activity and prognosis in systemic lupus erythematosus. Lupus (2000) 1.11
Molecular mechanisms and selection influence the generation of the human V lambda J lambda repertoire. J Immunol (1999) 1.10
Perturbations of peripheral B lymphocyte homoeostasis in children with systemic lupus erythematosus. Ann Rheum Dis (2003) 1.05
Use of immunoglobulin variable-region genes by normal subjects and patients with systemic lupus erythematosus. Int Arch Allergy Immunol (2000) 1.02
Immunoproteasome subunit LMP2 expression is deregulated in Sjogren's syndrome but not in other autoimmune disorders. Ann Rheum Dis (2006) 1.02
Peripheral B cell abnormalities and disease activity in systemic lupus erythematosus. Lupus (2008) 1.01
Systemic lupus erythematosus after heavy exposure to quartz dust in uranium mines: clinical and serological characteristics. Lupus (1996) 1.01
Proteasome alpha-type subunit C9 is a primary target of autoantibodies in sera of patients with myositis and systemic lupus erythematosus. J Exp Med (1996) 0.98
Validation of the sterilization procedure of allogeneic avital bone transplants using peracetic acid-ethanol. Biologicals (2001) 0.98
Association of immunoglobulin-like transcript 6 deficiency with Sjögren's syndrome. Arthritis Rheum (2009) 0.97
Influence of peptidylarginine deiminase type 4 genotype and shared epitope on clinical characteristics and autoantibody profile of rheumatoid arthritis. Ann Rheum Dis (2008) 0.96
Somatic hypermutation of VkappaJkappa rearrangements: targeting of RGYW motifs on both DNA strands and preferential selection of mutated codons within RGYW motifs. Eur J Immunol (1999) 0.95
Enhanced mutational activity and disturbed selection of mutations in V(H) gene rearrangements in a patient with systemic lupus erythematosus. Autoimmunity (2000) 0.94
Efficient tetanus toxoid immunization on vitamin D supplementation. Eur J Clin Nutr (2011) 0.93
Immune hemolysis-serological and clinical aspects. Clin Exp Med (2003) 0.93
CD22 ligation inhibits downstream B cell receptor signaling and Ca(2+) flux upon activation. Arthritis Rheum (2013) 0.93
Onset of psoriasis with psoriatic arthropathy during rituximab treatment of non-Hodgkin lymphoma. Ann Rheum Dis (2008) 0.89
Beneficial response to rituximab in a patient with haemolysis and refractory Felty syndrome. Ann Rheum Dis (2008) 0.88
Autoimmune reactivity against the 20S-proteasome includes immunosubunits LMP2 (beta1i), MECL1 (beta2i) and LMP7 (beta5i). Rheumatology (Oxford) (2008) 0.87
Autoantibodies in primary Sjögren's syndrome are directed against proteasomal subunits of the alpha and beta type. Arthritis Rheum (1999) 0.87
Targeting and selection of mutations in human Vlambda rearrangements. Eur J Immunol (2000) 0.87
Structurally derived mutations define congenital heart block-related epitopes within the 200-239 amino acid stretch of the Ro52 protein. Scand J Immunol (2005) 0.87
Smaller role for pol eta? Nat Immunol (2001) 0.86
Comparison of immunoglobulin heavy chain rearrangements between peripheral and glandular B cells in a patient with primary Sjögren's syndrome. Scand J Immunol (2003) 0.85
Prolactin enhances the in vitro production of IgG in peripheral blood mononuclear cells from patients with systemic lupus erythematosus but not from healthy controls. Ann Rheum Dis (2001) 0.85
The role of CD40-CD40 ligand (CD154) interactions in immunoglobulin light chain repertoire generation and somatic mutation. Clin Immunol (2001) 0.85
The influence of CD40-CD154 interactions on the expressed human V(H) repertoire: analysis of V(H) genes expressed by individual B cells of a patient with X-linked hyper-IgM syndrome. Int Immunol (2000) 0.84
Dissemination of a Sjögren's syndrome-associated extranodal marginal-zone B cell lymphoma: circulating lymphoma cells and invariant mutation pattern of nodal Ig heavy- and light-chain variable-region gene rearrangements. Arthritis Rheum (2006) 0.84
Treatment of acute exacerbation of systemic lupus erythematosus with high-dose intravenous immunoglobulin. Rheumatology (Oxford) (2000) 0.82
[Recommendations for use of rituximab in patients with rheumatoid arthritis]. Z Rheumatol (2014) 0.82
Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) - results from a nationwide cohort in Germany (GRAID). Lupus (2013) 0.82
[Sjögren syndrome]. Internist (Berl) (2010) 0.81
Immunoglobulin Vkappa light chain gene analysis in patients with Sjögren's syndrome. Arthritis Rheum (2001) 0.81
[Indications and options of new immune modulatory therapies for Sjögren's syndrome]. Z Rheumatol (2007) 0.80
Immunoglobulin Vlambda light chain gene usage in patients with Sjögren's syndrome. Arthritis Rheum (2001) 0.80
Similar characteristics of the CDR3 of V(H)1-69/DP-10 rearrangements in normal human peripheral blood and chronic lymphocytic leukaemia B cells. Br J Haematol (1998) 0.80
Complete heart block caused by primary Sjögren's syndrome and hypopituitarism. Ann Rheum Dis (1998) 0.80
Antinuclear antibody- and extractable nuclear antigen-related diseases. Int Arch Allergy Immunol (2000) 0.80
Anti-proteasome autoantibodies contribute to anti-nuclear antibody patterns on human larynx carcinoma cells. Ann Rheum Dis (2006) 0.79
Diagnostic importance of anti-proteasome antibodies. Int Arch Allergy Immunol (2000) 0.79
[Rituximab]. Z Rheumatol (2010) 0.79
[Biosimilars : Current state of the build up to series production]. Z Rheumatol (2013) 0.78
[Antiphospholipid syndrome 2007. Current aspects of laboratory diagnostics and their therapeutic consequences]. Z Rheumatol (2007) 0.78
Progressive multifocal leukoencephalopathy in a patient with undifferentiated systemic vasculitis and bilateral acute retinal necrosis. Clin Exp Rheumatol (2009) 0.77
Sufficient penetration of peracetic acid into drilled human femoral heads. Cell Tissue Bank (2005) 0.77
Longlasting effects of immunoadsorption in severe Sjögren's syndrome. Ann Rheum Dis (2004) 0.77
[Autoantibodies and antibody-secreting cells]. Z Rheumatol (2005) 0.76
[Intrauterine therapy and outcome in four pregnancies of one mother with anti ro-autoantibody positive Sjoegren's syndrome]. Z Geburtshilfe Neonatol (2002) 0.76
[Biologics therapy for systemic lupus erythematosus. Current situation]. Z Rheumatol (2015) 0.75
[Translational aspects on the role of B-cells in autoimmune diseases. "From bench to bedside" and "from bed to benchside"]. Z Rheumatol (2009) 0.75
[Rheumatology on the move]. Dtsch Med Wochenschr (2002) 0.75
Investigation of the anti-Ro autoantibody levels in patients with systemic lupus erythematosus. Clin Exp Rheumatol (1994) 0.75
[Macrophage activation syndrome]. Z Rheumatol (2012) 0.75
A unique autoantibody pattern of positive anti-Jo-1, anti-U1RNP, and antiproteasome antibodies in autoimmune myositis as a diagnostic challenge. Ann Rheum Dis (2003) 0.75
Enhanced frequency of autoimmune congenital heart block in female offspring. Rheumatology (Oxford) (1999) 0.75
[Successful therapeutic management of risk pregnancy in primary Sjögren syndrome with plasmapheresis and dexamethasone]. Z Rheumatol (1996) 0.75
Benefit of immunosuppression for severe Takayasu's arteritis and coincident primary biliary cirrhosis. Ann Rheum Dis (2004) 0.75
[Personalized medicine for rheumatoid arthritis : serological and clinical patient profiles to optimize B and T cell targeted therapy]. Z Rheumatol (2013) 0.75
[B-cell-directed therapy in patients with connective tissue diseases]. Dtsch Med Wochenschr (2012) 0.75
[Sjögren's syndrome]. Z Rheumatol (2010) 0.75
[Sjogren-Syndrome. Current developments from a rheumatologists point of view]. Hautarzt (2008) 0.75
[Current therapeutic options in Sjögren's syndrome]. Z Rheumatol (2010) 0.75